CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has successfully completed a Phase 3 clinical study for its denosumab biosimilar, showing no significant differences in efficacy compared to Prolia among 446 postmenopausal women, with potential regulatory filings planned for early 2026.